Lamivudine (generic), Epivir, Epivir-HBV News

Entecavir Has Reduced Activity in Hepatitis B Patients Failing Adefovir , but Resistance Is Rare in Treatment-naive People Chronic hepatitis B patients who still had detectable HBV viral load despite treatment with adefovir responded poorly to entecavir , indicating drug resistance.

There are currently several new anti-HIV drugs that have been approved by the U.S. Food and Drug Administration or that are in clinical testing.

Studies have consistently shown that HIV-HCV coinfected patients do not respond as well to interferon-based therapy as those with HCV monoinfection .

More Treatment News June 9, 2009 The experimental antiretroviral drug apricitabine has received approval from a data safety monitoring board to continue with its Phase III trial beyond week 16.

Gilead Fundamentally Strong By: Jason Napodano, CFA 0 ) Share Business continues to look strong for Gilead Sciences .

At the annual Digestive Disease Week meeting this week in Chicago, a panel of experts discussed the prevention and management of antiviral drug resistance in patients receiving long-term treatment for chronic hepatitis B virus infection , according to DDW Daily News, the official conference newspaper.

Some of these investigational agents work similarly to certain antiretroviral drugs for HIV , suggesting it may be possible to develop drugs that have activity against both HIV-HCV, a potential benefit for HIV-HCV coinfected patients .

Laboratory Study Shows Hepatitis B Drug Entecavir -- But Not Telbivudine -- Has Activity against Multiple Strains of HIV Several antiretroviral agents -- including tenofovir , lamivudine , and emtricitabine -- are active against both HIV and hepatitis B virus , and therefore are well-suited for treating HIV-HBV coinfected patients who require ...

At the 44th Annual Meeting of the European Association for the Study of the Liver last month in Copenhagen, Austrian researchers presented data from a study of highly active antiretroviral therapy in coinfected patients, showing that HIV-HBV coinfected people tolerate HAART well and achieve outcomes as good as those of HIV negative people with ...

Telbivudine is one of several nucleoside/nucleotide analog agents approved for the treatment of chronic hepatitis B virus infection .

The material posted on HIV and Hepatitis.com about EASL 2009 is not approved by nor is it a part of EASL 2009.

Due to overlapping transmission routes, a minority of people with HIV are also coinfected with hepatitis B virus .

In patients with hepatitis B e antigen-negative chronic hepatitis who are treated with peginterferon alfa-2a, on-treatment quantification of hepatitis B virus surface antigen may predict which patients are most likely to be cured, according to a report published in the April issue of Hepatology .

HBV is unusual in that it uses reverse transcriptase to replicate, a characteristic usually seen only in retroviruses such as HIV.

At the 13th International Symposium on Viral Hepatitis and Liver Disease last week in Washington, DC, experts in the field of viral hepatitis were asked to present their views on various issues.

While antiretroviral agents in novel classes have garnered the most attention in recent years, researchers continue to develop new drugs in existing classes.

More Treatment News March 19, 2009 Apricitabine - an experimental nucleoside reverse transcriptase inhibitor - can be used safely and effectively for nearly two years in combination with other antiretrovirals, according to a press release by Avexa Limited, the drug's developer.

People with chronic hepatitis B virus infection may experience "flares" or sudden increases in blood levels of alanine transaminase , an enzyme that indicates liver inflammation.

Telbivudine May Be Effective for Chronic Hepatitis B Treatment after Failure of Adefovir By Liz Highleyman Several nucleoside and nucleotide analog agents are active against hepatitis B virus , but development ...

Tenofovir -- one of the most widely used antiretroviral drugs for HIV -- was granted FDA approval in August 2008 as a treatment for chronic hepatitis B. As previously reported , Karine Lacombe presented data at ...